Syndax Pharmaceuticals Price To Sales vs. Market Capitalization

SNDX Stock  USD 16.73  0.64  3.98%   
Based on Syndax Pharmaceuticals' profitability indicators, Syndax Pharmaceuticals' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Syndax Pharmaceuticals' ability to earn profits and add value for shareholders.

Syndax Pharmaceuticals Price To Sales Ratio

6.97

Operating Cash Flow Sales Ratio is likely to rise to 0.25 in 2024, whereas Price To Sales Ratio is likely to drop 6.97 in 2024. At this time, Syndax Pharmaceuticals' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 21.6 M in 2024, despite the fact that Operating Income is likely to grow to (218.5 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.9
Fairly Down
Slightly volatile
For Syndax Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Syndax Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Syndax Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Syndax Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Syndax Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syndax Pharmaceuticals. If investors know Syndax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syndax Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.64)
Revenue Per Share
0.195
Quarterly Revenue Growth
332.974
Return On Assets
(0.49)
Return On Equity
(0.82)
The market value of Syndax Pharmaceuticals is measured differently than its book value, which is the value of Syndax that is recorded on the company's balance sheet. Investors also form their own opinion of Syndax Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syndax Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syndax Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syndax Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Syndax Pharmaceuticals Market Capitalization vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Syndax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Syndax Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Syndax Pharmaceuticals is rated second in price to sales category among its peers. It is currently regarded as top stock in market capitalization category among its peers creating about  16,000,006  of Market Capitalization per Price To Sales. At this time, Syndax Pharmaceuticals' Price To Sales Ratio is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Syndax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Syndax Market Capitalization vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Syndax Pharmaceuticals

P/S

 = 

MV Per Share

Revenue Per Share

 = 
85.84 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Syndax Pharmaceuticals

Market Cap

 = 

Shares Outstanding

X

Share Price

 = 
1.37 B
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Syndax Market Capitalization vs Competition

Syndax Pharmaceuticals is currently regarded as top stock in market capitalization category among its peers. Market capitalization of Health Care industry is at this time estimated at about 2.17 Billion. Syndax Pharmaceuticals totals roughly 1.37 Billion in market capitalization claiming about 63% of equities under Health Care industry.
Capitalization  Valuation  Revenue  Total debt  Workforce

Syndax Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Syndax Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Syndax Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Syndax Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Syndax Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income218 K228.9 K
Operating Income-230 M-218.5 M
Income Before Tax-209.4 M-198.9 M
Total Other Income Expense Net20.6 M21.6 M
Net Loss-209.4 M-198.9 M
Income Tax Expense-5 M-4.8 M
Net Loss-176.1 M-167.3 M
Net Loss-134.4 M-127.7 M
Interest Income18.6 M19.5 M
Net Interest Income18.4 M19.3 M
Non Operating Income Net Other695.8 K730.5 K
Change To Netincome16.1 M8.2 M
Net Loss(2.98)(3.12)
Income Quality 0.77  0.63 
Net Income Per E B T 1.11  1.09 

Syndax Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Syndax Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Syndax Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Syndax Pharmaceuticals' important profitability drivers and their relationship over time.

Use Syndax Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Syndax Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syndax Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Syndax Pharmaceuticals Pair Trading

Syndax Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Syndax Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Syndax Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Syndax Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Syndax Pharmaceuticals to buy it.
The correlation of Syndax Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Syndax Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Syndax Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Syndax Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Syndax Pharmaceuticals position

In addition to having Syndax Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Shipbuilding Railroad Equipment Thematic Idea Now

Shipbuilding Railroad Equipment
Shipbuilding Railroad Equipment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Shipbuilding Railroad Equipment theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Shipbuilding Railroad Equipment Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.